Guest Editors
Jinhua Wang, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. E-mail: wjh@imm.ac.cn
William Cho, Queen Elizabeth Hospital, Hong Kong, China. E-mail: williamcscho@gmail.com
Hongquan Wang, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. E-mail: whongquan@alu.fudan.edu.cn
Yan Pan, Department of Pharmacology in Peking University, Beijing, China. E-mail: pannay26@bjmu.edu.cn
Xiaoming Zhu, Macau University of Science and Technology, Macau, China. E-mail: xmzhu@must.edu.cn
Huanli Xu, Capital Medical University, Beijing, China. E-mail: xuhuanli@ccmu.edu.cn
Summary
Cancer is the second-leading cause of death in the world and becomes a serious health problem now. It is very important for treatment of cancer to identify new drug target and find new strategy.
This special issue covers the full range of therapeutic issues, from the early phase of new drug discovery, formulation, to the identification of therapeutically relevant targets and clinical trials.
Over the past decade, intravenous and oral administration of anticancer drugs have become an important part of currently used cancer medicines. However, optimizing drug delivery to provide sufficient systemic exposure to treat tumors while minimizing toxicity and tailoring concomitant therapy is still a challenge. Modern advance in enhancing the permeability and retention is needed.
Also, with the same drug, different patients may response in an unpredicted manner, it is important to address the treatment prediction and biomarker discovery.
In the special issue, the new target, drug, new treat strategy of cancer. The special issue will improve understanding of cancer mechanism and treatment.
Keywords
Target, treatment of cancer, cancer drug, cancer pharmacology, biomarkers
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue